Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Metastatic Melanoma
100%
Melanoma
75%
Immune Checkpoint Inhibitors
43%
Anti-programmed Cell Death Protein 1 (anti-PD-1)
36%
Tumor-infiltrating Lymphocytes
28%
National Cohort Study
25%
Anti-PD-1 Therapy
25%
Advanced Melanoma
24%
Overall Survival
22%
Nivolumab
19%
Checkpoint Inhibitors
19%
Adoptive Cell Therapy
18%
Dendritic Cell Vaccine
17%
Ipilimumab
16%
Clinical Trials
16%
Progression-free Survival
15%
Melanoma Patients
15%
BRAF/MEK Inhibition
14%
Adjuvant Therapy
13%
Complete Response
13%
Immune-related Adverse Events (IrAEs)
12%
Clinical Outcomes
12%
Interleukin-2
12%
Pembrolizumab
12%
Denmark
12%
Real Patients
11%
Adjuvant Immunotherapy
11%
Immune Checkpoint Therapy
10%
Anti-PD-1 Immunotherapy
10%
Melanoma Brain Metastases
10%
TILT-123
10%
Oncolytic Adenovirus
10%
Immune-related
10%
BRAF Inhibitor (BRAFi)
10%
Stage III-IV
9%
Recurrence-free Survival
9%
World Data
9%
Median Overall Survival
9%
Tumor-infiltrating Lymphocyte Therapy
9%
Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4)
9%
Tumor
8%
Adjuvant Setting
8%
Programmed Death-ligand 1 (PD-L1)
8%
Cutaneous Melanoma
8%
Partial Response
7%
Stable Disease
7%
Treatment Discontinuation
7%
Real-world Impact
7%
MEK Inhibitor (MEKi)
7%
Patient Survival
7%
Medicine and Dentistry
Melanoma
94%
Metastatic Melanoma
70%
Immune Checkpoint Inhibitor
33%
Immunotherapy
31%
Tumor Infiltrating Lymphocyte
24%
Overall Survival
23%
Progression Free Survival
21%
Diseases
17%
MEK Inhibitor
17%
Cohort Analysis
16%
Cell Therapy
15%
Recurrent Disease
14%
Adjuvant Therapy
11%
Clinical Trial
11%
Oncolytic Adenovirus
10%
T Cell
9%
Neoplasm
9%
Chemotherapy
9%
Positron Emission Tomography-Computed Tomography
9%
Uvea Melanoma
8%
Biological Marker
8%
Brain Metastasis
8%
Real-World Data
7%
Interleukin 2
7%
Recurrence Free Survival
7%
Biopsy Technique
7%
Programmed Death-Ligand 1
7%
Pembrolizumab
7%
Positron Emission Tomography
6%
Ipilimumab
6%
Melanoma Skin Cancer
6%
Nivolumab
6%
Median Follow Up
6%
Long Term Survival
5%
Tumor Vaccine
5%
Patient Population
5%